Tertinat
Phase 2Small molecule
Tertinat is one of 44 small molecule programs targeting Atherosclerosis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Atherosclerosis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Niacor
AbbVieApproved
Crestor
AstraZenecaApproved
Praluent
RegeneronApproved
Plavix
SanofiApproved
Aldactone
PfizerApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Onglyza
AstraZenecaApproved
Selzentry
GSKApproved
Actos
TakedaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atherosclerosis1 trial
Prospective Double-Blinded Randomized Placebo-controlled Multicenter Study Evaluating the Impact of Dietary Supplement "Tertinat" on Major Adverse Cardiovascular Events in ATherosclerotic Patients After Coronary Revascularization Surgery.
Active, not recruiting·IInstitute for Atherosclerosis Research, Russia·Phase 2·NCT06590012·1,228 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tertinat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details